Autism Spectrum Disorder (ASD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Autism Spectrum Disorder (ASD) Emerging Therapy and TPP Insights

Thelansis’s “Autism Spectrum Disorder (ASD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Autism Spectrum Disorder (ASD) Overview

Autism spectrum disorder (ASD) is a complex, highly heterogeneous neurodevelopmental condition clinically defined by two core diagnostic domains: persistent deficits in social communication and reciprocal interaction across multiple contexts, alongside the presence of restricted, repetitive patterns of behavior, interests, or activities. While the etiology is multifactorial—strongly linked to high heritability, advanced parental age, extreme prematurity, and specific genetic syndromes like Fragile X—the phenotypic expression varies profoundly across the spectrum, ranging from individuals requiring very substantial, lifelong support to those who are highly independent. Beyond the core behavioral differences, many individuals experience clinically significant sensory processing anomalies (hyper- or hyporeactivity to sensory input) and, in a distinct subset, a pronounced regression of previously acquired language or social skills during early childhood. In modern clinical practice, management has shifted toward a neurodiversity-affirming paradigm, utilizing highly individualized early interventions—encompassing speech-language pathology, occupational therapy, and targeted developmental supports—designed to maximize functional independence, support alternative communication, and improve the overall quality of life.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Autism Spectrum Disorder (ASD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026